White L, Sterling-Levis K, Kees U R, Tobias V
Children's Cancer Institute Australia, Sydney Children's Hospital and University of NSW, Randwick, Australia.
J Clin Neurosci. 2001 Mar;8(2):151-6. doi: 10.1054/jocn.2000.0734.
An important role for pre-clinical models of medulloblastoma/primitive neuroectodermal tumour (MB/PNET) is inhibited by the limitations of conventional heterotransplantation. Nine cohorts of MB/PNET were studied for subcutaneous engraftment in nude mice by both conventional and Matrigel supplemented methods. While no subcutaneous tumours resulted from 63 conventional attempts, an aggregate 41 xenografts from 72 injections (57%) were produced when Matrigel was added to the cell suspension. In subsequent passage, engraftment rate approached 100%. To study the response to chemotherapeutic agents in the model, a total of 221 tumours in 3 cohorts were treated using one of the following: cisplatin, carboplatin, vincristine, cyclophosphamide, diaziquone, or saline control. While all agents demonstrated statistically significant activity, cyclophosphamide proved to be particularly effective. The potential applications of this xenograft model in the biologic as well as therapeutic study of MB/PNET deserve continuing investigation.
髓母细胞瘤/原始神经外胚层肿瘤（MB/PNET）临床前模型的重要作用受到传统异种移植局限性的抑制。采用传统方法和补充基质胶的方法，对9组MB/PNET进行了裸鼠皮下移植研究。虽然63次传统尝试均未产生皮下肿瘤，但当在细胞悬液中添加基质胶时，72次注射共产生了41个异种移植物（57%）。在后续传代中，移植率接近100%。为了研究该模型对化疗药物的反应，对3组共221个肿瘤采用以下之一进行治疗：顺铂、卡铂、长春新碱、环磷酰胺、二嗪醌或生理盐水对照。虽然所有药物均显示出统计学上的显著活性，但环磷酰胺被证明特别有效。这种异种移植模型在MB/PNET生物学及治疗研究中的潜在应用值得持续研究。
